With markets closed today and Hurricane Sandy ravaging the Eastern Seaboard, investors looking forward to earnings reports from Pfizer (NYSE:PFE), Vertex Pharmaceuticals (NASDAQ:VRTX), Dendreon (NASDAQ:DNDN), and Acorda Therapeutics (NASDAQ:ACOR) will have to wait a little longer for their quarterly dose of financial metrics. Pfizer and Vertex have moved their release dates from Monday to Thursday. Accorda and Dendreon have delayed their previously scheduled Tuesday releases to Wednesday and Friday, respectively.
Still, there's no shortage of companies scheduled to release results in spite of the weather. While it remains likely that more delays will be announced, at the time of this writing, nine companies are scheduled to report today and 25 are scheduled for tomorrow.
Below is a list of scheduled health care industry earnings releases, according to Thomson Reuters StreetEvents.
Monday, Oct. 29:
ARRY, CHE, KND, LIFE, LMNX, OMI, FVE, HAE, MNKD.
Tuesday, Oct. 30:
ASTX, CERS, CRL, CSII, CYH, DVA, EPOC, GERN, MASI, MDAS, ONXX, PRXL, THRX, UAM, UHS, AGN, AVEO, CAH, CRVL, IPXL, MDSO, SPNC, CTIC, EXAC, EXAS.
Brenton Flynn owns no shares of the companies mentioned. The Motley Fool owns shares of Dendreon and Masimo. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.